This is inherent to the mechanism and does not diminish with continued use
Semaglutide: An Overview Semaglutide represents a paradigm shift in the treatment of type 2 diabetes and obesity, embodying the progress in our understanding and management of these conditions
People with severe kidney disease should use caution as limited safety data exists in this population
Figure 2: Novel Incretin Mimetic Assets for T2DM and Obesity in Phase 2/3 of Development Remaining Unmet Needs Remaining Unmet Needs Though the value proposition of on-market GLP-1 and dual-agonists is strong, several key unmet needs still exist for incretin mimetics across diabetes and obesity, namely: (1) improved efficacy, (2) better tolerability, (3) more convenient options / alternative ROAs, and (4) improved access and affordability
Patients may experience benefits including: Reduced hunger and cravings Improved portion control Better appetite regulation Significant weight reduction Improved metabolic health Our medical team closely monitors each patient throughout treatment to help optimize safety, effectiveness, and long-term success